Thursday, November 12, 2026

Ripple Targets 3-5 Second Private Settlements on XRP Ledger by Mid-2026 for Global Banks

Ripple will deploy zero-knowledge proof privacy layers directly on XRP Ledger's mainnet within 12 months, enabling 3-5 second settlements for institutional cross-border payments. The technology allows banks worldwide to process confidential transactions while providing regulators controlled access through cryptographic credentials.

Ripple Targets 3-5 Second Private Settlements on XRP Ledger by Mid-2026 for Global Banks
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Ripple will implement zero-knowledge proof privacy layers on XRP Ledger's mainnet, delivering 3-5 second settlement times for institutional payments while maintaining transaction confidentiality. Phase 1 deployment arrives within 12 months of October 2025, targeting mid-2026 adoption by banks across major payment corridors.

The architecture addresses a barrier slowing blockchain adoption in traditional banking: public ledgers expose transaction flows to competitors. Banks in Europe, Asia, and North America have cited privacy concerns when evaluating blockchain payment rails for cross-border transfers.

"The privacy layer enables banks to maintain confidentiality while providing regulators controlled access," Ripple stated. Zero-knowledge proofs validate transactions—verifying sender authorization, balances, and compliance—without exposing amounts, counterparties, or payment purposes to public observers.

The system runs on XRPL's main network rather than requiring sidechains or layer-2 solutions. This design preserves the ledger's existing speed while adding enterprise confidentiality features that financial institutions require for international payments.

Regulators receive access through cryptographic credentials rather than blanket visibility. This structure aims to satisfy compliance requirements from financial authorities in jurisdictions including the US, EU, and Asia-Pacific markets where Ripple operates payment corridors.

Industry analysts project the privacy architecture could drive 40%+ growth in RegTech AI solutions for real-time transaction monitoring by mid-2026. Banks using privacy-preserved blockchain rails will need upgraded systems that verify compliance without accessing full transaction details.

The 3-5 second settlement window matches current XRPL performance. Ripple keeps privacy computation on-chain rather than offloading to external processors that could introduce latency or centralization risks—a consideration for institutions moving high-value cross-border payments.

Ripple is expanding institutional partnerships to support the privacy rollout. The company's regulatory positioning targets compliance concerns that have slowed blockchain infrastructure adoption among licensed financial institutions operating across multiple jurisdictions.


Sources:
1 Globe Newswire, "ROSEN, SKILLED INVESTOR COUNSEL, Encourages uniQure N.V. Investors to Secure Counsel Before Importan" (March 23, 2026)
2 Nasdaq, "Renewed Consolidation Likely For Thai Stock Market" (March 23, 2026)
3 Globe Newswire, "ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel" (March 23, 2026)
4 Globe Newswire, "Thailand Repositions Its Exhibition Industry to Drive FDI and a $44.5bn Creative Economy" (March 23, 2026)
5 Nasdaq, "6 Surprising Stocks Affected by High Oil Prices" (March 22, 2026)

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com